{"id":62825,"date":"2026-03-21T01:02:27","date_gmt":"2026-03-21T00:02:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\/"},"modified":"2026-03-21T01:02:27","modified_gmt":"2026-03-21T00:02:27","slug":"curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\/","title":{"rendered":"Curi Bio and Battelle Announce Strategic Partnership to Accelerate the Adoption of New Approach Methods in Neuromuscular Pharmacology"},"content":{"rendered":"
\n

SEATTLE & COLUMBUS, Ohio–(BUSINESS WIRE)–#BioTech<\/a>–Curi Bio, a world leader in human-relevant 3D tissue technology, and Battelle, the world\u2019s largest independent nonprofit research and development organization, today announced a strategic partnership to commercialize next-generation Neuromuscular Junction (NMJ) assay technology. This collaboration combines Curi Bio\u2019s innovative microphysiological systems with Battelle\u2019s extensive GLP-ready infrastructure to offer a transformative, human-relevant alternative to traditional pharmacology methodologies.<\/p>\n

<\/a>
<\/a>
<\/a>
<\/a><\/p>\n

\nAdvancing the 3Rs: <\/b>At the core of this partnership is a commitment to the 3Rs (Replacement, Reduction, and Refinement). By providing functional, 3D human-tissue models that replicate complex neuromuscular physiology, the Curi Bio-Battelle partnership enables researchers to replace long-standing animal-based bioassays with highly reproducible new approach methods.<\/p>\n

\nInnovation Meets Infrastructure:<\/b> The partnership leverages Curi Bio\u2019s proven Mantarray\u2122 ecosystem which provides real-time functional readouts of human heart, muscle, and neuromuscular junction contractility. By offering a ready-to-use commercial solution for BoNT potency, Curi Bio enables customers to generate data with their specific drug products, accelerating the adoption of human-relevant, cell-based NMJ assays. Battelle serves as the scale and integration partner, offering the regulatory expertise and specialized laboratory facilities necessary to implement these technologies across global drug substance and medical countermeasure (MCM) development pipelines.<\/p>\n

\n\u201cWe are excited to partner with Battelle to scale our technology for applications with significant commercial and governmental utility,\u201d said Elliot Fisher, Chief Business Officer and Co-Founder of Curi Bio. \u201cWith the FDA\u2019s new Non-Animal Models (NAMs) guidance and the NIH\u2019s $150M commitment to human-relevant alternatives, the regulatory landscape is clearly shifting toward the scalable platforms we\u2019ve built. This partnership is a high priority as we set the new gold standard for potency testing with our human-relevant NMJ assay and position Curi Bio at the forefront of animal-free drug development.\u201d<\/p>\n

\n\u201cThe partnership shows how technology innovators and technology integrators can combine strengths to accelerate real-world adoption of new approach methods,\u201d said Bob Moyer, Research Leader at Battelle. \u201cBattelle brings R&D scale, regulatory expertise, and world-class laboratory capabilities, while Curi Bio contributes cutting-edge technology and transformative human relevant models\u2014together enabling innovation to translate into practical impact.\u201d<\/p>\n

\nAbout Curi Bio:<\/b> Curi Bio provides a suite of human-relevant 3D tissue models and instrumentation to accelerate drug discovery and development. By integrating human iPSCs, tissue engineering, and automated data analysis, Curi Bio helps researchers build more predictive models of human disease. For more information, visit www.curibio.com<\/a> or contact Marketing Director Jacqueline De Rose at jacqueline@curibio.com<\/a>.<\/p>\n

\nAbout Battelle:<\/b> Every day, the people of Battelle apply science and technology to solving what matters most. At major technology centers and national laboratories around the world, Battelle conducts research and development, designs and manufactures products, and delivers critical services for government and commercial customers. For more information, visit www.battelle.org<\/a> or contact Media Relations Director Katy Delaney at (614) 424-7208 or at delaneyk@battelle.org<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nCuri Bio
\n
<\/b>Jacqueline De Rose
\n
Marketing Director
\n
jacqueline@curibio.com<\/a>
www.curibio.com<\/a><\/p>\n

\nBattelle
\n
<\/b>Katy Delaney
\n
Media Relations Director
\n
(614) 424-7208
\n
delaneyk@battelle.org<\/a>
www.battelle.org<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SEATTLE & COLUMBUS, Ohio–(BUSINESS WIRE)–#BioTech–Curi Bio, a world leader in human-relevant 3D tissue technology, and Battelle, the world\u2019s largest independent nonprofit research and development organization, today announced a strategic partnership to commercialize next-generation Neuromuscular Junction (NMJ) assay technology. This collaboration combines Curi Bio\u2019s innovative microphysiological systems with Battelle\u2019s extensive GLP-ready infrastructure to offer a transformative, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62825","6":"format-standard","7":"category-industry"},"yoast_head":"\nCuri Bio and Battelle Announce Strategic Partnership to Accelerate the Adoption of New Approach Methods in Neuromuscular Pharmacology - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Curi Bio and Battelle Announce Strategic Partnership to Accelerate the Adoption of New Approach Methods in Neuromuscular Pharmacology - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SEATTLE & COLUMBUS, Ohio–(BUSINESS WIRE)–#BioTech–Curi Bio, a world leader in human-relevant 3D tissue technology, and Battelle, the world\u2019s largest independent nonprofit research and development organization, today announced a strategic partnership to commercialize next-generation Neuromuscular Junction (NMJ) assay technology. This collaboration combines Curi Bio\u2019s innovative microphysiological systems with Battelle\u2019s extensive GLP-ready infrastructure to offer a transformative, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-21T00:02:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260320032528\/en\/2753655\/22\/Curi-Bio-Batelle-PR.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Curi Bio and Battelle Announce Strategic Partnership to Accelerate the Adoption of New Approach Methods in Neuromuscular Pharmacology\",\"datePublished\":\"2026-03-21T00:02:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\\\/\"},\"wordCount\":521,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260320032528\\\/en\\\/2753655\\\/22\\\/Curi-Bio-Batelle-PR.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\\\/\",\"name\":\"Curi Bio and Battelle Announce Strategic Partnership to Accelerate the Adoption of New Approach Methods in Neuromuscular Pharmacology - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260320032528\\\/en\\\/2753655\\\/22\\\/Curi-Bio-Batelle-PR.jpg\",\"datePublished\":\"2026-03-21T00:02:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260320032528\\\/en\\\/2753655\\\/22\\\/Curi-Bio-Batelle-PR.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260320032528\\\/en\\\/2753655\\\/22\\\/Curi-Bio-Batelle-PR.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Curi Bio and Battelle Announce Strategic Partnership to Accelerate the Adoption of New Approach Methods in Neuromuscular Pharmacology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Curi Bio and Battelle Announce Strategic Partnership to Accelerate the Adoption of New Approach Methods in Neuromuscular Pharmacology - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\/","og_locale":"en_US","og_type":"article","og_title":"Curi Bio and Battelle Announce Strategic Partnership to Accelerate the Adoption of New Approach Methods in Neuromuscular Pharmacology - Pharma Trend","og_description":"SEATTLE & COLUMBUS, Ohio–(BUSINESS WIRE)–#BioTech–Curi Bio, a world leader in human-relevant 3D tissue technology, and Battelle, the world\u2019s largest independent nonprofit research and development organization, today announced a strategic partnership to commercialize next-generation Neuromuscular Junction (NMJ) assay technology. This collaboration combines Curi Bio\u2019s innovative microphysiological systems with Battelle\u2019s extensive GLP-ready infrastructure to offer a transformative, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\/","og_site_name":"Pharma Trend","article_published_time":"2026-03-21T00:02:27+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260320032528\/en\/2753655\/22\/Curi-Bio-Batelle-PR.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Curi Bio and Battelle Announce Strategic Partnership to Accelerate the Adoption of New Approach Methods in Neuromuscular Pharmacology","datePublished":"2026-03-21T00:02:27+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\/"},"wordCount":521,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260320032528\/en\/2753655\/22\/Curi-Bio-Batelle-PR.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\/","url":"https:\/\/pharma-trend.com\/en\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\/","name":"Curi Bio and Battelle Announce Strategic Partnership to Accelerate the Adoption of New Approach Methods in Neuromuscular Pharmacology - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260320032528\/en\/2753655\/22\/Curi-Bio-Batelle-PR.jpg","datePublished":"2026-03-21T00:02:27+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260320032528\/en\/2753655\/22\/Curi-Bio-Batelle-PR.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260320032528\/en\/2753655\/22\/Curi-Bio-Batelle-PR.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/curi-bio-and-battelle-announce-strategic-partnership-to-accelerate-the-adoption-of-new-approach-methods-in-neuromuscular-pharmacology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Curi Bio and Battelle Announce Strategic Partnership to Accelerate the Adoption of New Approach Methods in Neuromuscular Pharmacology"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62825"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62825\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62825"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62825"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}